Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07HKV
|
|||
| Former ID |
DIB011866
|
|||
| Drug Name |
IMGN-388
|
|||
| Synonyms |
Intetumumab-DM4; CNTO-95-DM4; Integrin-targeting antibody (TAP), Centocor; Integrin-targeting antibody (TAP), ImmunoGen
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Company |
Centocor Ortho Biotech Inc
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00721669) A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors. U.S. National Institutes of Health. | |||
| REF 2 | Anti-alphav integrin monoclonal antibody intetumumab enhances the efficacy of radiation therapy and reduces metastasis of human cancer xenografts in nude rats. Cancer Res. 2010 Oct 1;70(19):7591-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.